Patent office upholds key patent for Gilead's HIV drug

05/21/2008 | Boston Globe (tiered subscription model), The

Gilead Sciences announced that the U.S. Patent and Trademark Office has reaffirmed one of four key patents for its HIV drug Viread. The patents are being reassessed after being challenged by the Public Patent Foundation, which has claimed prior art. The patent office will likely uphold the other three patents, an analyst said.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD